---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-067650"
form_type: "8-K"
ticker: "SPRB"
cik: "0001683553"
company_name: "SPRUCE BIOSCIENCES, INC."
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:51:09.719983+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Spruce Biosciences Phase 2 POWER trial shows tildacerfont reduces DHEAS (p=0.020) and increases SHBG (p=0.012) in PCOS

## Summary
- 27 women with PCOS enrolled; tildacerfont titrated to 200 mg QD vs placebo for 12 weeks.
- In patients with elevated baseline DHEAS, geometric mean ratio vs placebo was 0.828 (p=0.020).
- SHBG increased 32.9% vs placebo -8.1% (LS mean ratio 1.446, p=0.012).
- Tildacerfont well-tolerated; no serious adverse events reported.
- Primary endpoint not powered for significance; results suggest therapeutic potential.

## SEC filing metadata
- accession: 0000950170-24-067650
- form_type: 8-K
- ticker: SPRB
- cik: 0001683553
- company_name: SPRUCE BIOSCIENCES, INC.
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1683553/000095017024067650/0000950170-24-067650-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1683553/000095017024067650/sprb-20240602.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-067650
- JSON: https://secwatch.observer/filing/0000950170-24-067650.json
- Plain text: https://secwatch.observer/filing/0000950170-24-067650.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.